Generic Ketek Availability
KETEK (telithromycin - tablet;oral)
Manufacturer: SANOFI AVENTIS US
Approval date: April 1, 2004
Strength(s): 400MG [RLD]
Manufacturer: SANOFI AVENTIS US
Approval date: February 9, 2005
Has a generic version of Ketek been approved?
No. There is currently no therapeutically equivalent version of Ketek available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Ketek. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Issued: June 3, 1997
Inventor(s): Agouridas; Constantin & Chantot; Jean-Francois & Denis; Alexis & D'Ambrieres; Solange G. & Martret; Odile L.
Assignee(s): Roussel Uclaf
An erythromycin compound of Formula I or its non-toxic acid addition salt having antibiotic activity.Patent expiration dates:
- April 1, 2018✓✓✓
- April 1, 2018
Issued: July 2, 2002
Inventor(s): Christian; Desesquelle & Philippe; Becourt
Assignee(s): Aventis Pharma S.A.Patent expiration dates:
- September 24, 2015✓
- September 24, 2015
- Ketek Consumer Information (Drugs.com)
- Ketek Consumer Information (Wolters Kluwer)
- Ketek Consumer Information (Cerner Multum)
- Ketek Advanced Consumer Information (Micromedex®)
- Ketek AHFS DI Monographs (ASHP)
- Telithromycin Consumer Information (Wolters Kluwer)
- Telithromycin Consumer Information (Cerner Multum)
- Telithromycin Advanced Consumer Information (Micromedex®)
- Telithromycin AHFS DI Monographs (ASHP)
|Drug Patent||A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.|
|Drug Exclusivity||Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.|
|RLD||A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.|